How Reimbursement Support Services Help Patients Access Specialty Therapies
- Shawn Thomas
- 8 minutes read
Specialty therapy access rarely depends on a prescription alone. Coverage may fall under a medical or pharmacy benefit, prior authorization may require clinical documentation, a denial may require an appeal, patient cost exposure may need to be clarified, and the prescription may need to move through a designated specialty pharmacy. Benefit identification, authorization requirements, patient financial responsibility, and coordination among prescribers, pharmacies, payers, and hubs are important parts of getting specialty medications to patients without avoidable delay.
For pharmaceutical commercial, patient access, and hub-services teams, reimbursement support services can connect those administrative steps into a more coherent access journey. The goal is not to guarantee coverage or replace payer or provider decision-making. It is to make the pathway clearer, coordinate required information, monitor case status, and help prevent patients from getting lost between prescription and therapy start.
Access Is a Connected Reimbursement Journey
A specialty therapy prescription can be the beginning of a complicated administrative process. Before treatment begins, the patient’s coverage may need to be identified, payer requirements confirmed, prior authorization completed, affordability options explored, and the prescription routed to the appropriate specialty pharmacy.
That complexity is one reason reimbursement support services can play an important role in specialty therapy access. Rather than treating each administrative task as a separate transaction, reimbursement support can help connect the steps and maintain visibility as a patient moves toward treatment.
One early challenge is simply determining how a therapy is covered. Specialty medications may fall under a patient’s medical benefit or pharmacy benefit, and that distinction can affect reimbursement requirements, prior authorization, dispensing, and patient cost sharing. NCPDP has identified timely and accurate benefit identification, including potential out-of-pocket costs, as an important opportunity to reduce manual work and improve time to therapy.
Benefits Investigation Creates the Access Roadmap
Benefits investigation is often the first substantive step in reimbursement support services because it establishes what needs to happen next.
A benefits investigation can help clarify active coverage, whether the therapy is processed through the medical or pharmacy benefit, applicable payer requirements, prior authorization needs, and expected patient financial responsibility. The information gathered at this stage can help providers, support teams, and specialty pharmacies understand the pathway before significant time is spent pursuing the wrong process.
This matters because fragmented benefit identification can involve repeated phone calls, portals, manual searches, and duplicated work across providers, pharmacies, and hub teams. Workflows should provide more comprehensive benefit information without multiple manual steps or duplication.
For a patient, the value is straightforward: fewer administrative surprises after the prescription has already entered the access process.
Prior Authorization and Appeals Need Organized Follow-Through
Prior authorization is one of the most visible access barriers associated with specialty medications. A systematic review of 44 studies examining specialty drug utilization found that prior authorization was associated with treatment delays, while higher patient cost sharing was generally associated with lower treatment initiation and persistence and greater abandonment.
The administrative burden is also substantial for provider offices. In the American Medical Association’s 2025 physician survey, respondents reported an average of 40 prior authorizations per physician per week and approximately 13 hours of physician and staff time devoted to that workload. Ninety-five percent reported that prior authorization delays access to necessary care. These figures are physician-reported survey results, but they illustrate why reducing avoidable back-and-forth can matter to both practices and patients.
Prior authorization support services can help by identifying payer requirements, gathering the necessary case information, coordinating documentation with the provider office, submitting or facilitating the request where appropriate, tracking status, and communicating next steps. Clinical decisions remain with qualified healthcare professionals, and authorization decisions remain with the payer.
A denial is not necessarily the end of the pathway. Appeals coordination may involve identifying the stated reason for denial, determining what supporting information is required, coordinating additional documentation with the provider, monitoring deadlines, and tracking the case through reconsideration. HHS Office of Inspector General reviews have found examples in Medicare Advantage where denied requests were later reversed after appeals or disputes, reinforcing the importance of accurate documentation and a structured process for responding to denials.
| Reimbursement support component | Purpose | Typical tasks | Impact on access |
|---|---|---|---|
| Benefits investigation | Establish the patient’s coverage pathway | Verify coverage, identify medical vs. pharmacy benefit, review payer requirements and patient cost exposure | Clarifies next steps earlier and can reduce duplicated or misdirected work |
| Prior authorization support | Coordinate requirements for payer review | Identify criteria, collect required information, coordinate documentation, submit or facilitate requests, monitor status | Helps reduce incomplete submissions and administrative delays |
| Appeals coordination | Support an organized response to a denial | Review denial reason, coordinate additional documentation, monitor deadlines and case status | Creates a defined path for reconsideration rather than allowing the case to stop at denial |
Affordability and Specialty Pharmacy Coordination Complete the Path
Coverage approval does not necessarily mean a patient can immediately begin therapy. The patient’s out-of-pocket responsibility may still create an access barrier, and specialty pharmacy requirements can add another handoff.
Research on specialty medications has found a relationship between higher cost sharing and medication abandonment, while programs that lower patient cost exposure have been associated with greater initiation and persistence. The specific affordability resources available depend on factors such as insurance status, program eligibility, applicable laws, and program terms.
Reimbursement support can help patients understand the financial responsibility identified during benefits investigation and, where appropriate, navigate available affordability resources. This may involve coordination with manufacturer assistance programs or other support pathways without making assumptions about eligibility.
The next challenge is fulfillment. Specialty medications can involve pharmacy network restrictions, limited distribution arrangements, additional patient onboarding, delivery coordination, or other requirements. Research into specialty pharmacy turnaround time has identified prior authorization, patient communication, prescriber issues, financial assistance, and formulary requirements among factors that can slow the process. Coordination across pharmacies, providers, and other stakeholders is therefore important to maintaining continuity.
A well-connected reimbursement support services workflow can follow the case across those transitions rather than ending once an authorization is approved:
This continuity becomes particularly important when something changes. A payer may request additional information. An authorization may be denied. A patient’s coverage may change. A specialty pharmacy may need clarification before dispensing. Follow-up gives the access team an opportunity to identify those issues while there is still a clear next action.
The broader direction of reimbursement administration also points toward greater workflow integration. CMS has finalized interoperability requirements intended to streamline prior authorization for many medical items and services, and in 2026 proposed extending similar electronic prior authorization capabilities to drugs covered under medical benefits. The proposal reflects the continuing industry focus on reducing fragmented documentation and improving the speed and transparency of authorization workflows.
For specialty therapies, the important lesson is that reimbursement is not one administrative event. It is a sequence of dependent steps. Reimbursement support services can help make those steps visible, organized, and connected so patients, providers, pharmacies, and support teams know what needs to happen next.
Practical Recommendations
For organizations designing or evaluating a reimbursement support model, three practices deserve particular attention:
Establish the coverage pathway early. Confirm the applicable benefit, payer requirements, authorization needs, and likely patient cost exposure before the case moves through multiple downstream teams. Early, accurate benefit identification as an opportunity to reduce duplication and delays.
Treat prior authorization and appeals as one continuous workflow. Build status tracking, documentation requirements, denial reasons, deadlines, and provider follow-up into the same case process rather than treating an appeal as an entirely new transaction. CMS’s prior authorization initiatives similarly emphasize better information exchange and greater process transparency.
Measure the handoffs, not only completed tasks. Track whether a patient successfully progresses from benefits investigation to authorization, affordability support, pharmacy coordination, and ultimately therapy start. Delays can arise at multiple points, including communication, authorization, formulary, financial assistance, and pharmacy fulfillment.